|Bid||10.88 x 800|
|Ask||15.99 x 2200|
|Day's Range||10.87 - 11.73|
|52 Week Range||9.65 - 27.84|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.44|
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Flexion Therapeutics, Inc. (FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the third consecutive year. Flexion was the only Boston-area biopharmaceutical company recognized in the medium business category (100 to 249 employees). “There is tremendous competition for talent in the biotech industry, and awards like this differentiate Flexion and give us an advantage when it comes to attracting and retaining top talent,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion.
BURLINGTON, Mass., June 18, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
The Compensation Committee of the Board of Directors approved the grants with an effective date of June 3, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $11.13 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
Flexion Therapeutics, Inc. (FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645 for FX201, the company's gene therapy product candidate. U.S. Patent No. 10,301,645 was awarded to Baylor College of Medicine in Houston, Texas. In December of 2017, Flexion acquired the global rights to FX201 from GeneQuine Biotherapeutics GmbH, and as part of that agreement, Flexion obtained an exclusive license to the underlying intellectual property rights from Baylor for human applications.
Flexion Therapeutics, Inc. (NASDAQ:FLXN) shareholders should be happy to see the share price up 12% in the last month...
BURLINGTON, Mass., May 14, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
Flexion Therapeutics, Inc. (FLXN) today announced that a pooled analysis of data from three Phase 2/3 randomized clinical trials on the use of rescue medications with ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Pain and Therapy. The analysis indicated that rescue medication use was significantly lower following a single injection of ZILRETTA, the first and only extended-release intra-articular therapy for OA knee pain, in comparison to placebo and TAcs.
The spotlight is on Uber today as the company makes its stock market debut. Many investors look at Uber with interest due to its disruptive potential and the fact that the transportation sector is so big. While Uber is commanding the spotlight, traders are also talking about several other stocks including Conduent Incorporated (NYSE:CNDT), Chevron Corporation (NYSE:CVX), Anadarko […]
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 3.54% and -4.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of $1.09. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
BURLINGTON, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2019. “Flexion delivered solid ZILRETTA sales performance in the first quarter of 2019,” said Michael Clayman, M.D., President and Chief Executive Officer. “While we were pleased with our first-quarter results, we are particularly encouraged by the trajectory of the launch, as demonstrated by the preliminary net sales of approximately $5.1 million in April.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Flexion Therapeutics, Inc. (NASDAQ: FLXN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...
Repeat Administration of Triamcinolone Acetonide Extended-Release Affords Consistent, Clinically Relevant Improvements in Pain: Results from a Phase 3b, Single-Arm, Open-Label.
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its first-quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, May 8, 2019. Flexion Therapeutics (FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
Flexion Therapeutics, Inc. (FLXN) today announced that the results from a post-hoc analysis of data from the pivotal Phase 3 trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Advances in Therapy. The findings indicated that patients with unilateral osteoarthritis (OA) knee pain experienced significant and durable pain relief with a single intra-articular injection of ZILRETTA compared to immediate-release triamcinolone acetonide in crystalline suspension (TAcs), as measured by Average Daily Pain (ADP) intensity scores.
Investors are always looking for growth in small-cap stocks like Flexion Therapeutics, Inc. (NASDAQ:FLXN), with a market cap of US$389m. However, an important fact which most ignore is: how financially healthy is the business...